Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
1.
J Child Neurol ; 33(13): 832-836, 2018 11.
Article in English | MEDLINE | ID: mdl-30182801

ABSTRACT

Three children with drug-refractory epilepsy, normal magnetic resonance image (MRI), and a heterozygous SCN1A variant underwent 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography (FDG-PET) scanning between age 6 months and 1 year and then at age 3 years 6 months to 5 years 5 months. Regional FDG uptake values were compared to those measured in age- and gender-matched pseudo-controls. At baseline, the brain glucose metabolic pattern in the SCN1A group was similar to that of the pseudo-controls. At follow-up, robust decreases of normalized FDG uptake was found in bilateral frontal, parietal and temporal cortex, with milder decreases in occipital cortex. Children with epilepsy and an SCN1A variant have a normal pattern of cerebral glucose metabolism at around 1 year of age but develop bilateral cortical glucose hypometabolism by age 4 years, with maximal decreases in frontal, parietal, and temporal cortex. This metabolic pattern may be characteristic of epilepsy associated with SCN1A variants and may serve as a biomarker to monitor disease progression and response to treatments.


Subject(s)
Brain/metabolism , Epilepsy/genetics , Glucose Metabolism Disorders/genetics , Mutation/genetics , NAV1.1 Voltage-Gated Sodium Channel/genetics , Brain/diagnostic imaging , Child , Child, Preschool , Epilepsy/complications , Epilepsy/diagnostic imaging , Female , Fluorodeoxyglucose F18/pharmacokinetics , Glucose Metabolism Disorders/complications , Glucose Metabolism Disorders/diagnostic imaging , Humans , Longitudinal Studies , Male , Positron-Emission Tomography , Retrospective Studies
2.
J Alzheimers Dis ; 60(1): 225-233, 2017.
Article in English | MEDLINE | ID: mdl-28826182

ABSTRACT

BACKGROUND: Weight loss is frequently observed in patients with Alzheimer's disease (AD); however, the underlying mechanisms are not well understood. OBJECTS: To clarify the associations between nutritional status and AD-related brain changes using Pittsburgh Compound-B (PiB)-PET, fluorodeoxyglucose (FDG)-PET, and structural MRI. METHODS: The subjects were 34 amyloid-ß (Aß)-positive individuals with mild cognitive impairment or early AD (prodromal/early AD), and 55 Aß-negative cognitively normal (CN) subjects who attended the Multimodal Neuroimaging for AD Diagnosis (MULNIAD) study. Nutritional status of the subjects was assessed by body mass index and waist to height ratio (waist circumference/height). The associations between nutritional status and brain changes were examined by multiple regression analysis using statistical parametric mapping. RESULTS: In the prodromal/early AD group, nutritional status was significantly positively correlated with regional cerebral glucose metabolism (rCGM) in the medial prefrontal cortices, while different topographical associations were seen in the CN group, suggesting these changes were AD-specific. Aß deposition and gray matter volume were not significantly associated with nutritional status. Sub-analysis in the prodromal/early AD group demonstrated that fat mass index, but not fat-free mass index, was positively correlated with rCGM in the medial prefrontal areas. CONCLUSION: This present study provides preliminary results suggesting that hypometabolism in the medial prefrontal areas is specifically associated with AD-related weight loss, and decrease in fat mass may have a key role.


Subject(s)
Alzheimer Disease/pathology , Alzheimer Disease/physiopathology , Glucose Metabolism Disorders/etiology , Nutritional Status/physiology , Prefrontal Cortex/metabolism , Prodromal Symptoms , Aged , Alzheimer Disease/diagnostic imaging , Aniline Compounds/metabolism , Cognition Disorders/etiology , Female , Glucose Metabolism Disorders/diagnostic imaging , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Positron-Emission Tomography , Prefrontal Cortex/diagnostic imaging , Psychiatric Status Rating Scales , Thiazoles/metabolism
3.
Int J Mol Sci ; 17(10)2016 Oct 18.
Article in English | MEDLINE | ID: mdl-27763550

ABSTRACT

Alzheimer's disease (AD) is a leading cause of dementia worldwide, associated with cognitive deficits and brain glucose metabolic alteration. However, the associations of glucose metabolic changes with cognitive dysfunction are less detailed. Here, we examined the brains of APP/presenilin 1 (PS1) transgenic (Tg) mice aged 2, 3.5, 5 and 8 months using 18F-labed fluorodeoxyglucose (18F-FDG) microPET to assess age- and brain region-specific changes of glucose metabolism. FDG uptake was calculated as a relative standardized uptake value (SUVr). Morris water maze (MWM) was used to evaluate learning and memory dysfunction. We showed a glucose utilization increase in multiple brain regions of Tg mice at 2 and 3.5 months but not at 5 and 8 months. Comparisons of SUVrs within brains showed higher glucose utilization than controls in the entorhinal cortex, hippocampus, and frontal cortex of Tg mice at 2 and 3.5 months but in the thalamus and striatum at 3.5, 5 and 8 months. By comparing SUVrs in the entorhinal cortex and hippocampus, Tg mice were distinguished from controls at 2 and 3.5 months. In MWM, Tg mice aged 2 months shared a similar performance to the controls (prodromal-AD). By contrast, Tg mice failed training tests at 3.5 months but failed all MWM tests at 5 and 8 months, suggestive of partial or complete cognitive deficits (symptomatic-AD). Correlation analyses showed that hippocampal SUVrs were significantly correlated with MWM parameters in the symptomatic-AD stage. These data suggest that glucose metabolic disorder occurs before onset of AD signs in APP/PS1 mice with the entorhinal cortex and hippocampus affected first, and that regional FDG uptake increase can be an early biomarker for AD. Furthermore, hippocampal FDG uptake is a possible indicator for progression of Alzheimer's cognition after cognitive decline, at least in animals.


Subject(s)
Alzheimer Disease/diagnostic imaging , Amyloid beta-Protein Precursor/genetics , Brain/diagnostic imaging , Glucose Metabolism Disorders/diagnostic imaging , Presenilin-1/genetics , Aging , Alzheimer Disease/genetics , Alzheimer Disease/metabolism , Alzheimer Disease/pathology , Animals , Brain/metabolism , Brain/pathology , Cognition , Disease Models, Animal , Female , Fluorodeoxyglucose F18/analysis , Glucose/analysis , Glucose/metabolism , Glucose Metabolism Disorders/genetics , Glucose Metabolism Disorders/metabolism , Glucose Metabolism Disorders/pathology , Hippocampus/diagnostic imaging , Hippocampus/metabolism , Hippocampus/pathology , Humans , Maze Learning , Memory Disorders/diagnostic imaging , Memory Disorders/genetics , Memory Disorders/metabolism , Memory Disorders/pathology , Mice, Inbred C57BL , Mice, Transgenic , Mutation , Positron-Emission Tomography
4.
BMC Psychiatry ; 15: 157, 2015 Jul 11.
Article in English | MEDLINE | ID: mdl-26163145

ABSTRACT

BACKGROUND: With aging of society the absolute number and the proportion of patients with cognitive deficits increase. Multiple disorders and diseases can foster cognitive impairment, e.g., Alzheimer's disease (AD), depressive disorder, or polypharmacy. CASE PRESENTATION: A 74 year old man presented to the Old Age Psychiatry Service with cognitive deficits while being treated for recurrent depressive episodes and essential tremor with Venlafaxine, Lithium, and Primidone. Neuropsychological testing revealed a medio-temporal pattern of deficits with pronounced impairment of episodic memory, particularly delayed recall. Likewise, cognitive flexibility, semantic fluency, and attention were impaired. Positron emission tomography (PET) with fluorodeoxyglucose was performed and revealed a pattern of glucose utilization deficit resembling AD. On cessation of treatment with Lithium and Primidone, cognitive performance improved, particularly episodic memory performance and cognitive flexibility. Likewise, glucose metabolism normalized. Despite normalization of both, clinical symptoms and glucose utilization, the patient remained worried about possible underlying Alzheimer's disease pathology. To rule this out, an amyloid-PET was performed. No cortical amyloid was observed. CONCLUSION: Pharmacological treatment of older subjects may mimic glucose metabolism and clinical symptoms of Alzheimer's disease. In the present case both, imaging and clinical findings, reversed to normal on change of treatment. Amyloid PET is a helpful tool to additionally rule out underlying Alzheimer's disease in situations of clinical doubt even if clinical or other imaging findings are suggestive of Alzheimer's disease.


Subject(s)
Antidepressive Agents/adverse effects , Cognition Disorders/chemically induced , Depressive Disorder, Major/drug therapy , Glucose Metabolism Disorders/chemically induced , Memory Disorders/chemically induced , Aged , Alzheimer Disease/diagnostic imaging , Anticonvulsants/adverse effects , Attention/drug effects , Cognition Disorders/diagnostic imaging , Depressive Disorder, Major/diagnostic imaging , Diagnosis, Differential , Drug Therapy, Combination , Essential Tremor/drug therapy , Fluorodeoxyglucose F18 , Glucose Metabolism Disorders/diagnostic imaging , Humans , Lithium Compounds/adverse effects , Male , Memory Disorders/diagnostic imaging , Memory, Episodic , Mental Recall/drug effects , Neuropsychological Tests , Positron-Emission Tomography/methods , Primidone/adverse effects , Radiopharmaceuticals , Recurrence , Venlafaxine Hydrochloride/adverse effects
5.
Clin Exp Ophthalmol ; 43(8): 711-9, 2015 Nov.
Article in English | MEDLINE | ID: mdl-25904022

ABSTRACT

BACKGROUND: It has recently become clear that glaucoma is not only an ocular disease, but involves central visual pathways as well. The purpose of this study was to examine functional and structural alterations in the brains of glaucoma patients. DESIGN: Case-control study in a hospital. PARTICIPANTS: A total of 32 glaucoma patients and 19 healthy controls. METHODS: All participants underwent positron emission tomography with (18)F-fluorodeoxyglucose, diffusion-tensor magnetic resonance imaging, and the 30-2 program of the Humphrey Visual Field Analyzer. MAIN OUTCOME MEASURES: Fractional anisotropy values of the optic radiation were compared between the two groups by defining regions of interests. Cerebral glucose metabolism was compared using statistical parametric mapping software. The correlation coefficients were calculated between the average of the total deviation of hemivisual fields of both eyes, fractional anisotropy values of the contralateral optic radiation and glucose metabolism in the contralateral striate cortex. RESULTS: Fractional anisotropy values in the bilateral optic radiations were significantly lower in patients with glaucoma. A significant glucose hypometabolism in the bilateral striate cortex was also observed in the glaucoma group. Regression analyses for glaucoma patients demonstrated that the average of the total deviation of hemivisual fields significantly correlated with both fractional anisotropy value of the contralateral optic radiation and glucose metabolism in the contralateral striate cortex. Moreover, there were significant correlations between fractional anisotropy values of the optic radiation and ipsilateral striatal glucose metabolism. CONCLUSION: We observed structural alterations in the bilateral optic radiations and glucose hypometabolism in the bilateral striate cortex of glaucoma patients.


Subject(s)
Glaucoma/metabolism , Glucose Metabolism Disorders/metabolism , Optic Nerve Diseases/metabolism , Vision Disorders/metabolism , Visual Cortex/metabolism , Visual Fields , Adult , Aged , Aged, 80 and over , Anisotropy , Blood Glucose/metabolism , Case-Control Studies , Diffusion Magnetic Resonance Imaging , Female , Fluorodeoxyglucose F18/administration & dosage , Glaucoma/diagnostic imaging , Glucose Metabolism Disorders/diagnostic imaging , Humans , Male , Middle Aged , Optic Nerve Diseases/diagnostic imaging , Positron-Emission Tomography , Prospective Studies , Vision Disorders/diagnostic imaging , Visual Cortex/diagnostic imaging , Visual Field Tests
6.
J Alzheimers Dis ; 25(3): 517-23, 2011.
Article in English | MEDLINE | ID: mdl-21471644

ABSTRACT

Intracerebroventricular injection of streptozotocin (icv-STZ) in rodents induces cellular and behavioral features mimicking Alzheimer's disease (AD). However, the effect of icv-STZ in terms of regional cerebral glucose metabolism has not yet been examined in vivo. Given that regionally specific hypometabolism of glucose is a consistent neuroimaging marker in early AD, we monitored 18F-deoxyglucose uptake using a high-resolution micro-PET after icv-STZ in non-human primates. Two cynomolgus monkeys (Macaca fascicularis) received STZ (2 mg/kg), and another two were given normal saline as controls, at the cerebellomedullary cistern (CM) three times (day 1, 7, and 14). FDG-PET, as well as MRI for structural evaluation, was performed immediately before, six weeks after, and 12 weeks after the first icv injection. In the STZ group, FDG uptake decreased significantly in comparison to the pre-injection baseline, at the precuneus, the posterior cingulate, and medial temporal cortices. Increase in sulcal markings suggesting brain atrophy was observed by MRI at six weeks post-injection. The structural changes normalized at 12 weeks, but the reduced FDG uptake persisted at the same loci. The cortical distribution of glucose hypometabolism was similar to that at early stages of AD patients. The findings demonstrate that the effect of icv-STZ is regionally specific, lending further support for the method as a model of AD pathogenesis.


Subject(s)
Alzheimer Disease/complications , Brain/pathology , Glucose Metabolism Disorders/etiology , Glucose Metabolism Disorders/pathology , Streptozocin/toxicity , Alzheimer Disease/chemically induced , Animals , Brain/diagnostic imaging , Brain/drug effects , Brain Mapping , Disease Models, Animal , Fluorodeoxyglucose F18 , Glucose Metabolism Disorders/diagnostic imaging , Injections, Intraventricular , Macaca fascicularis , Magnetic Resonance Imaging , Positron-Emission Tomography/methods , Time Factors
7.
Neurobiol Aging ; 29(5): 676-92, 2008 May.
Article in English | MEDLINE | ID: mdl-17222480

ABSTRACT

OBJECTIVE: This longitudinal study used FDG-PET imaging to predict and monitor cognitive decline from normal aging. METHODS: Seventy-seven 50-80-year-old normal (NL) elderly received longitudinal clinical examinations over 6-14 years (561 person-years, mean per person 7.2 years). All subjects had a baseline FDG-PET scan and 55 subjects received follow-up PET exams. Glucose metabolic rates (MRglc) in the hippocampus and cortical regions were examined as predictors and correlates of clinical decline. RESULTS: Eleven NL subjects developed dementia, including six with Alzheimer's disease (AD), and 19 declined to mild cognitive impairment (MCI), on average 8 years after the baseline exam. The baseline hippocampal MRglc predicted decline from NL to AD (81% accuracy), including two post-mortem confirmed cases, from NL to other dementias (77% accuracy), and from NL to MCI (71% accuracy). Greater rates of hippocampal and cortical MRglc reductions were found in the declining as compared to the non-declining NL. CONCLUSIONS: Hippocampal MRglc reductions using FDG-PET during normal aging predict cognitive decline years in advance of the clinical diagnosis. Future studies are needed to increase preclinical specificity in differentiating dementing disorders.


Subject(s)
Aging/metabolism , Cognition Disorders/metabolism , Dementia/diagnostic imaging , Fluorodeoxyglucose F18/pharmacokinetics , Glucose Metabolism Disorders/metabolism , Glucose/metabolism , Hippocampus/metabolism , Aged , Aged, 80 and over , Cognition Disorders/complications , Cognition Disorders/diagnostic imaging , Dementia/metabolism , Female , Glucose Metabolism Disorders/complications , Glucose Metabolism Disorders/diagnostic imaging , Hippocampus/diagnostic imaging , Humans , Male , Middle Aged , Radionuclide Imaging , Radiopharmaceuticals/pharmacokinetics , Statistics as Topic
9.
Ann Nucl Med ; 19(3): 231-4, 2005 May.
Article in English | MEDLINE | ID: mdl-15981677

ABSTRACT

A 65-year-old male with an old cerebral contusion in the frontal lobes had suffered from status complex partial seizures. Ictal positron emission tomography with an F-18 fluorodeoxyglucose ([18F]FDG-PET) scan revealed hypermetabolism in the frontal, temporal and parietal lobes and the contralateral cerebellar hemisphere. The patient underwent a next-day PET scan with the 15O-labeled gas inhalation technique, which showed mild hyperperfusion and oxygen hypermetabolism in these areas. An interictal [18F]FDG-PET scan 17 days after the initial epilepsy demonstrated glucose hypometabolism of the frontal, temporal and parietal lobes and the contralateral cerebellar hemisphere. Increased glucose metabolism on the interictal PET scan and decreased glucose metabolism on an interictal PET scan in the epileptogenic supratentorial zones and the contralateral cerebellar hemisphere are interesting observations for understanding the pathophysiology in long-standing partial seizures.


Subject(s)
Cerebellum/diagnostic imaging , Cerebral Cortex/diagnostic imaging , Epilepsy/diagnostic imaging , Fluorodeoxyglucose F18 , Glucose Metabolism Disorders/diagnostic imaging , Aged , Brain Injuries/complications , Cerebellum/metabolism , Cerebral Cortex/metabolism , Epilepsy/etiology , Epilepsy/metabolism , Fluorodeoxyglucose F18/pharmacokinetics , Glucose/metabolism , Glucose Metabolism Disorders/etiology , Glucose Metabolism Disorders/metabolism , Humans , Male , Positron-Emission Tomography/methods , Radiopharmaceuticals/pharmacokinetics
10.
J Neurol Sci ; 215(1-2): 71-4, 2003 Nov 15.
Article in English | MEDLINE | ID: mdl-14568131

ABSTRACT

OBJECTIVE: To investigate the cerebral glucose metabolism of subjects who had a Clinical Dementia Rating (CDR) of 0.5, we studied 40 subjects whose CDR was 0.5 and 40 age-matched healthy subjects. METHODS: Cerebral glucose image of each subject was obtained by [18F]-2-fluoro-deoxy-D-glucose (FDG) positron emission tomography (PET). The anatomically standardized images were produced with NEUROSTAT. Then, the two groups were compared with the Statistical Parametric Mappings (SPM) 99. RESULTS: A comparison with the SPM 99 revealed that relative cerebral glucose metabolism was lower in the posterior cingulate gyri and parietal lobules in the CDR 0.5 group than in the healthy subjects group. CONCLUSION: These findings are very similar to those in patients with probable Alzheimer's disease (AD) and suggest that the majority of subjects with CDR 0.5 are suffering from very mild AD or at least a prodromal state of AD.


Subject(s)
Dementia/diagnostic imaging , Dementia/psychology , Glucose Metabolism Disorders/diagnostic imaging , Glucose Metabolism Disorders/psychology , Psychiatric Status Rating Scales , Aged , Dementia/metabolism , Female , Glucose Metabolism Disorders/metabolism , Humans , Male , Middle Aged , Psychiatric Status Rating Scales/statistics & numerical data , Tomography, Emission-Computed/methods
SELECTION OF CITATIONS
SEARCH DETAIL
...